Investigational Drug Information for LY3214996
What is the development status for investigational drug LY3214996?
LY3214996 is an investigational drug.
There have been 10 clinical trials for LY3214996.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 28th 2020.
The most common disease conditions in clinical trials are Pancreatic Neoplasms, Colorectal Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and Loxo Oncology, Inc.
There are nine US patents protecting this investigational drug and forty-two international patents.
Summary for LY3214996
| US Patents | 9 |
| International Patents | 42 |
| US Patent Applications | 41 |
| WIPO Patent Applications | 49 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2020-09-28) |
| Vendors | 51 |
Recent Clinical Trials for LY3214996
| Title | Sponsor | Phase |
|---|---|---|
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers | Lustgarten Foundation | Phase 1 |
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers | The Netherlands Cancer Institute | Phase 1 |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Loxo Oncology, Inc. | Phase 1 |
Clinical Trial Summary for LY3214996
Top disease conditions for LY3214996
Top clinical trial sponsors for LY3214996
US Patents for LY3214996
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LY3214996 | ⤷ Start Trial | ERK inhibitor and use thereof | Betta Pharmaceuticals Co Ltd | ⤷ Start Trial |
| LY3214996 | ⤷ Start Trial | Method for producing cardiomyocytes | Kyoto Prefectural PUC , Kataoka Corp | ⤷ Start Trial |
| LY3214996 | ⤷ Start Trial | Diacylglycerol kinase modulating compounds | Carna Biosciences Inc , Gilead Sciences Inc | ⤷ Start Trial |
| LY3214996 | ⤷ Start Trial | Methods for cancer detection and monitoring | Natera Inc | ⤷ Start Trial |
| LY3214996 | ⤷ Start Trial | Diacylglycerol kinase modulating compounds | Carna Biosciences Inc , Gilead Sciences Inc | ⤷ Start Trial |
| LY3214996 | ⤷ Start Trial | Heterocyclic compounds and uses thereof | Kumquat Biosciences Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LY3214996
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LY3214996 | Argentina | AR102977 | 2034-12-22 | ⤷ Start Trial |
| LY3214996 | Australia | AU2015369983 | 2034-12-22 | ⤷ Start Trial |
| LY3214996 | Brazil | BR112017011130 | 2034-12-22 | ⤷ Start Trial |
| LY3214996 | Canada | CA2966559 | 2034-12-22 | ⤷ Start Trial |
| LY3214996 | Chile | CL2017001514 | 2034-12-22 | ⤷ Start Trial |
| LY3214996 | China | CN107108648 | 2034-12-22 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
